6月26日，部分创新药公司披露的BD（商务拓展）落地情况或与市场乐观预期存在差距，创新药板块本 周初反弹后再度下跌。业内人士认为，创新药研发本身具有高度不确定性，尤其在当前部分个股估值已 较高的情况下，任何瑕疵都可能被放大并导致股价回调。具有更高置信度、更优竞争格局、更完备商业 逻辑的创新药企业才是具备更好投资逻辑的标的。 "吸金"力度加大 今年以来，在创新药行情的持续催化下，医药板块迎来久违的上涨行情。在累积较多涨幅后，港股创新 药板块开始带头回调，进入了高位震荡阶段，然而场内资金却呈现出"越跌越买"的迹象。 Wind数据显示，6月16日至6月20日，港股创新药指数大跌8.51%。在此期间，广发中证香港创新药 ETF、汇添富国证港股通创新药ETF分别净流入8.89亿元、7.10亿元。 ● 本报记者 王鹤静 近一周多以来，国内创新药板块结束此前单边上涨行情，转而进入震荡。然而，中国证券报记者发现， 场内资金却呈现出"越跌越买"的迹象。6月16日至6月25日，医药主题ETF合计净流入超64亿元，多只龙 头创新药主题ETF净流入超15亿元。 华夏基金策略团队分析，与此前BD公布后刺激板块上涨不同，本次荣昌生物跌幅 ...

今日港股集体回调，继四连涨后，港股通创新药ETF(159570)跌超2.5%，成交额快速突破13亿元！资金汹涌流入，港股通创新药ETF(159570)盘中净流入1.36 亿元，最新规模超75亿元强势领先同类，创上市以来新高！ 消息面上，荣昌生物今早宣布，将公司具有自主知识产权的泰它西普有偿许可给美国纳斯达克上市公司Vor Bio，Vor Bio将获得泰它西普在除大中华区以外 的全球范围内开发、生产和商业化的独家权利；荣昌生物将取得Vor Bio价值1.25亿美元现金及认股权证（包括4500万美元的首付款和价值8000万美元的认股 权证，认股权证可以每股0.0001美元认购Vor Bio 3.2亿股的普通股，约占Vor Bio经扩大总发行股本的23%）、最高可达41.05亿美元的里程碑付款，总金额 42.3亿美元，此外荣昌生物还将收到高个位数至双位数销售提成款。 受消息影响，荣昌生物低开近15%，盘中一度跌超22%。值得关注的是，此前4个交易日荣昌生物累涨超34%。港股通创新药ETF(159570)标的指数其他成分 股也多数飘绿：信达生物跌近4%，据今晨公告，信达生物拟折价4.9%配售5500万股，预计净筹42 ...

1、本轮创新药行情是对创新药商业模式的认可，是基于众多龙头公司如百济神州、信达生物、恒瑞医药等在2024年或2025Q1通过BD或者全球化带来公司 扭亏的认知，是一轮长久期资金认可并买入的典型贝塔行情，是标准清晰的产业趋势投资，市场对创新药企盈利模式可持续性的信心提升，行业基本面呈现 积极改善态势。 2、本轮创新药龙头股的集体上涨，反映了市场对其长期研发投入价值的系统性重估。过去多年积累的研发资产价值逐步得到认可，推动了创新药板块整体 估值中枢的上移。这一轮行情的驱动力主要源于对产业升级的长期预期，而非单纯依赖学术会议的数据披露事件。即使学术会议周期结束，支撑行情的核心 逻辑——研发价值的持续兑现与产业趋势的明朗化——仍有望延续。 3、当今的创新药行情是数据资产定价而非BD定价，BD是加速数据价值催化剂并非定价基准，只要研发资产数据优质且全球领先，市场自会给予其合理市 值，即使短期内BD节奏波动，创新药整体行情不会受到太大影响。 截至2025年6月25日 10:21，中证医药及医疗器械创新指数(931484)下跌0.31%。成分股方面涨跌互现，新产业(300832)领涨1.39%，特宝生物(688278)上涨 ...

Core Viewpoint - The announcement of the second employee stock ownership plan by TianKang aims to enhance long-term incentive mechanisms, improve employee cohesion and corporate competitiveness, and deeply bind the interests of the company, shareholders, and employees [1] Summary by Relevant Sections Employee Stock Ownership Plan - The scale of the employee stock ownership plan is set between RMB 150 million and RMB 200 million, with an average purchase price based on the closing price of RMB 33.77 per share on June 20, 2025, leading to a minimum of approximately 4.44 million shares and a maximum of about 5.92 million shares, accounting for no more than 1.39% of the total share capital as of the announcement date [1] - The holding period for the stock is strictly regulated, with a minimum of 12 months required [1] Market Confidence and Stock Performance - Industry insiders highlight three key points regarding TianKang's equity incentive: the stock will be sourced through secondary market purchases, the buy-in scale is significant, and the plan reflects strong confidence in future development [2] - TianKang's stock price has surged by 130% this year, ranking fourth among innovative drug concept stocks [2] Innovation and Clinical Development - The collective rise of innovative drug leaders reflects a systematic re-evaluation of the long-term value of R&D investments, driven by expectations of industry upgrades rather than solely academic data disclosures [3] - TianKang's innovative drug CKBA for vitiligo has completed 100% subject enrollment in its Phase II clinical trial, with plans to explore additional indications in the next 3-5 years [3] Growth Areas - The company is focusing on several growth areas, including gastrointestinal drugs, sexual health, and ophthalmology [4] - In the gastrointestinal sector, TianKang aims to expedite the registration process for its product and target over RMB 1 billion in sales within 3-5 years [4] - The sexual health segment features leading products with significant market presence, and a new product is expected to enhance the company's portfolio [4] - In ophthalmology, the company is progressing with clinical trials for a product aimed at treating presbyopia, which could become the first of its kind in China [4] Overall Outlook - TianKang's employee stock ownership plan reflects the company's strong confidence in future growth, driven by innovation and clinical needs, while building high-value competitive barriers in core areas [5] - As key projects move towards commercialization, the company is expected to generate new performance growth points and enter a new growth cycle [5]

证券研究报告 | 行业周报 gszqdatemark 2025 06 15 年 月 日 医药生物 MNC 账上还有多少钱？还有啥可能布局？【创新药大牛市】分支 思路（一）中国超市更新【周专题&周观点】【总第 401 期】 一、当周（6.9-6.13）回顾与周专题： 当周（6.9-6.13）申万医药指数环比+1.40%，跑赢创业板指数，跑赢沪深 300 指数。 本周周报，我们对 MNC 账上现金以及潜在布局进行了梳理。 二、近期复盘： 1、当周表现：本周市场整体震荡，石油有色领涨，医药涨幅靠前，港股医药涨幅更好， 创新药仍然是重中之重，前半周围绕"PD1 plus、减肥药、潜在 BD、中小市值爆款" 演绎，后半周，二三线创新药标的全面扩散，中药企业中有创新药管线的、CRO 公司 也都涨幅不错。周五迎来比较大的调整，核心标的比较坚挺，二三线标的调整较多。 2、原因分析：今年宏观逻辑不强，但流动性很好，创新药板块在连续大 BD 的刺激下 展现出来的产业趋势逻辑比较优势，不断虹吸市场资金，从活跃资金到稳健资金都逐步 参与到创新药板块演绎过程中，导致创新药成为市场表现最亮眼的板块。细分来看，近 期大 BD 主要围绕 P ...